MRK
Merck’s courtroom detour hits a wall
Merck tried to knock out the federal government’s Medicare drug price negotiation program on constitutional grounds. The court basically said: nice try, but no — denying Merck’s summary judgment motion and siding with the government.
Why this matters
This isn’t just legal theater. The Inflation Reduction Act gives Medicare the power to negotiate maximum fair prices for certain high-spend drugs, which is a fancy way of saying Big Pharma doesn’t get to charge whatever it wants forever.
For Merck, that means:
- less pricing flexibility on eligible drugs
- more pressure on future margins if more of its portfolio gets pulled into the program
- a reminder that Washington still has a hand on the steering wheel
The fine print that keeps pharma up at night
Merck had argued the setup was unconstitutional — citing takings, compelled speech, and unconstitutional conditions. The court wasn’t buying it, which keeps the negotiation framework intact for now.
And the penalties for opting out aren’t exactly subtle. The program can hit manufacturers with escalating excise taxes if they refuse to play ball, which is basically the policy version of “you can sit out the game, but the bill keeps coming anyway.”
Big picture
Merck shares were only slightly down in premarket trading, so this isn’t a sell-the-farm moment. But the ruling reinforces a broader truth: the era of untouchable drug pricing is getting a lot more negotiable.